Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMPUGEN LTDCGEN · Entity 6149 | Director | July 29, 2026 | July 30, 2026 |
| Gamida Cell Ltd.GMDA · Entity 94655 | Director | February 08, 2023 | February 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMPUGEN LTD
Report date July 29, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.26 · Expires 2036-07-29 | Direct | 100,000 |
Reported balance
After 2026-07-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-29 · Grant · Acquired 100,000 · Balance 100,000 F1: This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
Gamida Cell Ltd.
Report date February 08, 2023 · Filed February 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 32,300 |
Reported balance
After 2023-02-08 transaction · row 1
1 source rowRow 1 · 2023-02-08 · Grant · Acquired 28,300 · Balance 32,300 F1: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2033-02-07 | Direct | 56,600 |
Reported balance
After 2023-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-08 · Grant · Acquired 56,600 · Balance 56,600 F2: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date.
F2: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 30, 2026 20:09 UTC | COMPUGEN LTD CGEN · Entity 6149 | GrantShare Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.26 | $0.00 |
DisclosureSEC source: 0001178913-26-003723 · zk2635773.xml · derivative · entry 1 Cohen-Dayag Anat · CIK 0001907035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2036-07-29 F1 · derivative.exercise_date: This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 19:24 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantShare Option (Right to Buy) · Derivative | 56,600 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-008543 · doc4.xml · derivative · entry 2 Cohen-Dayag Anat · CIK 0001907035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,600 Underlying: Ordinary Shares · 56,600 shares Expires 2033-02-07 F2 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period, with the first such installment vesting on May 8, 2023, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 19:24 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 28,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-008543 · doc4.xml · nonDerivative · entry 1 Cohen-Dayag Anat · CIK 0001907035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,300 F1 · shares: Represents a restricted share unit award, which shall vest on February 8, 2024, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 28, 2022 Filed Jan 31, 2022 17:17 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $2.93 | $0.00 |
DisclosureSEC source: 0001209191-22-005661 · doc4.xml · derivative · entry 2 Cohen-Dayag Anat · CIK 0001907035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Ordinary Shares · 19,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: This option vests in equal quarterly installments over a twelve-month period commencing on April 28, 2022, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| January 28, 2022 Filed Jan 31, 2022 17:17 UTC | Gamida Cell Ltd. GMDA · Entity 94655 | GrantOrdinary Shares | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005661 · doc4.xml · nonDerivative · entry 1 Cohen-Dayag Anat · CIK 0001907035 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.